Quality of care: From measurement to improvement

Clinical and Experimental Rheumatology

Volumn 25, Issue 6 SUPPL. 47, 2007, Pages

  Mikuls, Ted R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Gout; Guidelines; Process indicators; Quality of care

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BENZBROMARONE; COLCHICINE; DIURETIC AGENT; FENOFIBRATE; INDOMETACIN; LOSARTAN; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; STEROID; SULFINPYRAZONE; URATE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL PROTOCOL; COMORBIDITY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FOLLOW UP; GOUT; HEALTH CARE QUALITY; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; OUTCOMES RESEARCH; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; EVIDENCE BASED MEDICINE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; GOUT; HUMANS; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

EID: 36448931659     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. MIKULS T, FARRAR J, BILKER W, FERNANDES S, SCHUMACHER HJ, SAAG K: Gout epidemiology: Results from the U.K. General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72.
2. ROBERTS C, ADEBAJO A, LONG S: Improving the quality of care of musculoskeletal conditions in primaiy care. Rheumatology 2002; 41: 503-8.
3. WOLFE F, CATHEY M: The misdiagnosis of gout and hyperuricemia. J Rheumatol 1991; 18: 1232-4.
4. VON ESSEN R, HOLTTA A, PIKKARAINEN R: Quality control of synovial fluid crystal identification. Ann Rheum Dis 1998; 57: 107-9.
5. GORDON C, SWAN A, DIEPPE P: Detection of crystals in synovial fluids by light microscopy: Sensitivity and reliability. Ann Rheum Dis 1989; 48: 737-42.
6. CHIN M, WANG L, JIN L et al.: Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med 1999; 6: 1232-42.
7. EVANS T, WHEELER M, SMALL R, BREITBACH S, SANDERS K, ROBERTS N: A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol 1996; 23: 143-8.
8. HANDE K, NOONE R, STONE W: Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.
9. STAMP L, GOW P, SHARPLES K, RAILL B: The optimal use of allopurinol: An audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30: 567-72.
10. SMITH P, KARLSON N, NAIR B: Quality use of allopurinol in the elderly. J Qual Clin Pract 2000; 20: 42-3.
11. DEVLIN J, BELLAMY N, BAYLIFF C: Observations and effects of educational consults on allopurinol prescribing. Can J Hosp Pharm 1992; 45: 21-7.
12. MIKULS T, CURTIS J, ALLISON J, HICKS R, SAAG K: Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous Internet-accessible error reporting program. J Rheumatol 2006; 33: 562-6.
13. ZHANG W, DOHERTY M, PASCUAL E et al.: EULAR evidence-based recommendations for gout. Part I. Diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-11.
14. ZHANG W, DOHERTY M, BARDIN T et al.: EULAR evidence-based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-24.
15. WALLACE S, ROBINSON H, MASI A, DECKER J, MCCARTY D, YU T: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
16. KELLGREN J, JEFFEREY M, BALL J: The Epidemiology of Chronic Rheumatism, Oxford, Blackwell, 1963.
17. BENNETT P and WOOD P (Eds.): Population Studies of the Rheumatic Diseases. Proceedings of the 3rd International Symposium. Amsterdam, Exerpta Medica Foundation, 1968.
18. WALLACE S, SINGER J: Review: Systemic toxicity associated with the IV administration of colchicine - guidelines for use. J Rheumatol 1988: 495-9.
19. ROEMJINDERS H, GORTER K: Dutch general practitioners gout guidelines. Ned Tijd Genees 2002; 146: 309-13.
20. NAKAJIMA H, MATSUZAWA Y: Introduction of the new guideline for the management of hyperuricemia and gout with special reference to its policy. Jpn J Clin Med 2003; 61 (Suppl.): 442-9.
21. MEYERS O, CASSIM B, MADY G: Hyperuricaemia and gout: Clinical guidelines. S Afr Med J 2003; 93: 961-71.
22. ZHANG W, DOHERTY M, ARDEN N et al.: EULAR evidence-based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669-81.
23. MIKULS T, MACLEAN C, OLIVIERI J et al.: Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937-43.
24. SHEKELLE P, MACLEAN C, MORTON S, WENGER N: Assessing care of vulnerable elders: Methods for developing quality indicators. Ann Intern Med 2001; 135 (Suppl.): 647-52.
25. MIKULS T, FARRAR J, BILKER W, FERNANDES S, SAAG K: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD). Rheumatology 2005; 44: 1038-42.
26. SARAWATE C, BREWER K, YANG W et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006: 81: 925-34.
27. HALPERN R, MIKULS T, SAAG K, MODY R, PATEL P: Assessment of quality of care in gout using claims data. Arthritis Rheum 2006; 54 (Suppl.): s700.
28. SCHUMACHER HJ, EDWARDS L, PEREZ-RUIZ F et al.: Outcome measures for acute and chronic gout. J Rheumatol 2005; 32: 2452-5.
29. SAAG K, MIKULS T: Recent advances in the epidemiology of gout. Curr Rheumatol Rep 2005; 7: 235-41.
30. AROMDEE E, MICHET C, CROWSON C, O'FALLON M, GABRIEL S: Epidemiology of gout: Is the incidence rising? J Rheumatol 2002; 29: 2403-6.
31. HARRIS C, LLOYD C, LEWIS J: The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48: 1153-8.
32. KLEMP P, STANSFIELD S, CASTLE B. ROBERTSON M: Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-6.
33. SUNDY J, GANSON N, KELLY S et al.: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56: 1021-8.
34. BECKER M, SCHUMACHER HJ, WORTMANN R et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-61.